Indrayani Biotech Limited (IBL) released Q1 financial results showing mixed performance. Standalone net profit slightly increased to ₹12.77 crore, but revenue fell 38% to ₹668.57 crore. Consolidated results were more challenging, with revenue dropping 7.7% to ₹2,910.37 crore and net profit declining 81.6% to ₹15.65 crore. Standalone EPS remained stable at ₹0.03, while consolidated EPS decreased from ₹0.10 to ₹0.03. The company's board meeting was held on August 14, 2025, and statutory auditors provided an unmodified opinion on the results.